Skip to main content

Definium Therapeutics, Inc.

corporate_fare Company Profile

Definium Therapeutics, Inc.

DFTX·NASDAQ·Life Sciences·CIK 0001813814

DT Pharma Inc. is a late-stage clinical biopharmaceutical company focused on developing new product candidates for brain health disorders. The company aims to develop accessible treatments by applying scientific methods to psychedelics. DT Pharma Inc. is building a pipeline of innovative product candidates that target neurotransmitter pathways important in brain health disorders. These include pharmaceutically optimized candidates derived from psychedelic and empathogen drug classes, such as DT120 (formerly MM120) and DT402 (formerly MM402), which are its lead product candidates. The company's first lead product candidate, DT120 ODT, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate. It is being developed to treat adults with generalized anxiety disorder (GAD) and major depressive disorder. In December 2023, DT Pharma Inc. reported positive topline results from its Phase 2b clinical trial of DT120 for GAD. The trial achieved its primary endpoint, showing statistically significant and clinically meaningful dose-dependent improvements on the Hamilton Anxiety Rating Scale ("HAM-A") compared to placebo at Week 4. In March 2024, the U.S. Food and Drug Administration ("FDA") granted breakthrough designation to the DT120 program for GAD. Also in March 2024, the company announced that its Phase 2b clinical trial of DT120 in GAD met its key secondary endpoint, with 12-week topline data demonstrating clinically and statistically significant durability of activity through Week 12. In September 2025, the full results from the Phase 2b clinical trial of DT120 in GAD were published in the Journal of the American Medical Association. In June 2024, DT Pharma Inc. completed its End-of-Phase 2 meeting with the FDA, supporting the progression of DT120 into pivotal trials for adults with GAD. The Phase 3 clinical program for DT120 ODT is expected to include two clinical trials: the Voyage study (DT120-300) and the Panorama study (DT120-301).

Definium Therapeutics, Inc. (NASDAQ:DFTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for DFTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 17 rated 8 or above. Recent SEC coverage for DFTX spans 8-K, 424B5, 10-Q.

Recent high-impact activity:

  • Definium Posts $51.0M Q3 Loss; $1.05B Cash Funds Operations Into 2030
  • Definium Posts $1.05B Cash Pile, Adds Positive DT402 Autism Data in Q3 Update
  • Definium Therapeutics Announces Positive Phase 3 Panorama Study Results for DT120 ODT in Generalized Anxiety Disorder
  • Definium's LSD Drug Shows Strong Anxiety Reduction in Second Late-Stage Trial
  • FDA Grants Second Breakthrough Therapy Designation for DT120 in Major Depressive Disorder

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$183.79M
Diluted EPS
-$2.06
Op. Cash Flow
-$131.56M
Operating Income
-$166.31M
Cash & Equivalents
$257.84M
Debt / Equity
0.00×
Shares Outstanding
98.78M sh
Source: 10-K · filed 2026-02-26 · accession 0001193125-26-076742

Short Interest & Short Volume

5.77 days to cover

FINRA reported short interest of 9,613,993 shares in DFTX as of the October 30, 2026 settlement, a 4.3% decrease from the prior period — about 5.8 days to cover at its recent average daily volume. On November 20, 2026, 78.3% of DFTX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)9,613,993 shares as of October 30, 2026
Change vs prior period▼ 4.3%
Days to cover5.77 at avg daily volume of 1,664,944
Daily short volume (FINRA facilities)78.3% of 1,067,688 shares on November 20, 2026
5-day average short volume68.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

High risk

Filing-implied dilution signals for DFTX, detected from its recent SEC filings · based on capital-structure filings through 2026-06-24.

1 recent capital raise

$500 Million Public Offering Announced · Strategic Timing with Positive Phase 3 Results

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with D →
$28.05 -1.02% today
52-week range · as of 2026-11-09 $10.46 – $49.7
Market cap
$3.88B
Volume
3.2M (1.8× avg)
3-mo avg 1.8M
Live data · 2026-11-21 16:55 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed DFTX - Latest Insights

DFTX
Nov 09, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $36.00
Real-time Price: $28.05 info
Change: -$7.95 (-22%) info
Market Cap: $3.88B info
DFTX
Nov 09, 2026, 4:01 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $35.36
Real-time Price: $28.05 info
Change: -$7.30 (-21%) info
Market Cap: $3.88B info
DFTX
Sep 14, 2026, 8:02 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $45.00
Real-time Price: $28.05 info
Change: -$16.95 (-38%) info
Market Cap: $3.88B info
DFTX
Sep 14, 2026, 7:00 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $41.46
Real-time Price: $28.05 info
Change: -$13.41 (-32%) info
Market Cap: $3.88B info
DFTX
Sep 08, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $39.39
Real-time Price: $28.05 info
Change: -$11.34 (-29%) info
Market Cap: $3.88B info
DFTX
Aug 12, 2026, 7:42 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $49.20
Real-time Price: $28.05 info
Change: -$21.15 (-43%) info
Market Cap: $3.88B info
DFTX
Aug 06, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $43.98
Real-time Price: $28.05 info
Change: -$15.93 (-36%) info
Market Cap: $3.88B info
DFTX
Jun 24, 2026, 5:23 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $42.34
Real-time Price: $28.05 info
Change: -$14.29 (-34%) info
Market Cap: $3.88B info
DFTX
Jun 24, 2026, 5:14 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $42.40
Real-time Price: $28.05 info
Change: -$14.35 (-34%) info
Market Cap: $3.88B info
DFTX
Jun 24, 2026, 5:10 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $42.11
Real-time Price: $28.05 info
Change: -$14.06 (-33%) info
Market Cap: $3.88B info
DFTX
Jun 23, 2026, 9:58 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $36.18
Real-time Price: $28.05 info
Change: -$8.13 (-22%) info
Market Cap: $3.88B info
DFTX
Jun 22, 2026, 6:40 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $35.00
Real-time Price: $28.05 info
Change: -$6.95 (-20%) info
Market Cap: $3.88B info
DFTX
Jun 22, 2026, 4:18 PM EDT
Filing Type: 424B5
Importance Score:
9
Price at Filing: $35.90
Real-time Price: $28.05 info
Change: -$7.85 (-22%) info
Market Cap: $3.88B info
DFTX
Jun 22, 2026, 8:01 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $33.02
Real-time Price: $28.05 info
Change: -$4.97 (-15%) info
Market Cap: $3.88B info
DFTX
Jun 22, 2026, 7:00 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $34.42
Real-time Price: $28.05 info
Change: -$6.37 (-19%) info
Market Cap: $3.88B info
DFTX
Jun 12, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $24.75
Real-time Price: $28.05 info
Change: +$3.30 (+13%) info
Market Cap: $3.88B info
DFTX
May 19, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $20.70
Real-time Price: $28.05 info
Change: +$7.35 (+36%) info
Market Cap: $3.88B info
DFTX
May 12, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $21.56
Real-time Price: $28.05 info
Change: +$6.49 (+30%) info
Market Cap: $3.88B info
DFTX
May 07, 2026, 4:17 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $22.86
Real-time Price: $28.05 info
Change: +$5.19 (+23%) info
Market Cap: $3.88B info
DFTX
May 07, 2026, 4:12 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $22.73
Real-time Price: $28.05 info
Change: +$5.32 (+23%) info
Market Cap: $3.88B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets